232 related articles for article (PubMed ID: 26060126)
1. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection.
di Meo N; Stinco G; Fadel M; Errichetti E; Trevisan G
J Cutan Med Surg; 2015; 19(3):203-4. PubMed ID: 26060126
[No Abstract] [Full Text] [Related]
2. Erythema annulare centrifugum due to pegylated interferon-α-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Gönül M; Külcü Çakmak S; Ozcan N; Deniz Oǧuz I; Ozhamam E
J Cutan Med Surg; 2014; 18(1):65-8. PubMed ID: 24377478
[TBL] [Abstract][Full Text] [Related]
3. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
4. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
5. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Crespo G; Lens S
Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
Lee SS; Kilvert L; Liu H; Trepanier J
Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X;
Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
9. Severe renal impairment during triple therapy with telaprevir.
Carrier P; Chambaraud T; Vong C; Guillaudeau A; Debette-Gratien M; Jacques J; Legros R; Sautereau D; Essig M; Loustaud-Ratti V
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):e69-71. PubMed ID: 24461554
[No Abstract] [Full Text] [Related]
10. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
11. [Chronic hepatitis C: improved cure rates with new approved medications].
Grammatikos G; Vermehren J; Zeuzem S
MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
[No Abstract] [Full Text] [Related]
12. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
13. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Moreno A; Quereda C; Montes M; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Dronda F; Bárcena R; Del Campo S; Moreno S
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e47-9. PubMed ID: 23095936
[No Abstract] [Full Text] [Related]
14. [Information for patients. Treatment of acute hepatitis C].
Otón Nieto E
Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
[No Abstract] [Full Text] [Related]
15. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Bacon BR; Khalid O
Liver Int; 2012 Feb; 32 Suppl 1():51-3. PubMed ID: 22212572
[TBL] [Abstract][Full Text] [Related]
16. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
17. "Hepatitis C (HCV) treatment is not a "one size fits all".
Bukeirat FA; Bukeirat MM
W V Med J; 2012; 108(2):20, 22-4. PubMed ID: 22655431
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
[No Abstract] [Full Text] [Related]
19. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Pawlotsky JM
Gastroenterology; 2011 Mar; 140(3):746-54. PubMed ID: 21255572
[No Abstract] [Full Text] [Related]
20. Re: "Erythema Annulare Centrifugum due to Pegylated Interferon-α-2a plus Ribavirin Combination Therapy in a Patient with Chronic Hepatitis C Virus Infection".
Naccarato M; Yoong D; Solomon R; Ostrowski M
J Cutan Med Surg; 2015; 19(1):10. PubMed ID: 25775656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
